Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells $139,454.10 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the transaction, the director now owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Amneal Pharmaceuticals Stock Up 2.4 %

Shares of AMRX opened at $8.06 on Thursday. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.01 and a 52-week high of $9.48. The stock has a fifty day simple moving average of $8.24 and a two-hundred day simple moving average of $8.03. The company has a market capitalization of $2.50 billion, a PE ratio of -11.85 and a beta of 1.10.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Truist Financial increased their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Gladius Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $37,000. DekaBank Deutsche Girozentrale purchased a new position in Amneal Pharmaceuticals in the second quarter worth approximately $42,000. Xponance Inc. acquired a new stake in Amneal Pharmaceuticals during the second quarter worth $65,000. Quest Partners LLC purchased a new stake in Amneal Pharmaceuticals in the third quarter valued at $84,000. Finally, Profund Advisors LLC lifted its stake in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after purchasing an additional 1,680 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.